Background: Microglial NADPH oxidase 2 (Nox2) expression is critical for nerve injuryinduced spinal cord microglia activation and subsequent pain hypersensitivity.
and p38 activation, and thereby may contribute to spinal cord microglia activation.
A series of studies have demonstrated that spinal cord glial cells play a critical role in the development of neuropathic pain after peripheral nerve injury (1) . Activation of spinal cord glia in the absence of peripheral nerve injury enhanced pain sensitivity (2) , and inhibition of these cells attenuated pain behavior in a neuropathic pain model (3) . It was later reported that proinflammatory cytokines or growth factors expressed by activated spinal cord glia such as TNF-α, IL-1β, IL-6, and BDNF facilitate pain hypersensitivity by inducing central sensitization at the spinal cord level (4, 5) . Studies on the mechanisms of spinal cord microglia activation have proposed that various transmembrane receptors, including CX3CR1, a fractalkine receptor (6) , and P2X 4 , an ATP receptor (7) , can potentially respond to nerve injury and trigger microglia activation. We have also proposed that Toll-like receptor 2 (TLR2) may trigger the proinflammatory activation of spinal cord microglia during peripheral nerve injury (8) . Likewise, TLR3 and 4 have been implicated in the activation of spinal cord microglia during the development of nerve injury-induced neuropathic pain (9, 10) .
At the level of intracellular signaling, p38 activation seems to be a key event in the activation of microglia upon nerve injury. Microglia activation mostly accompanies p38 activation (11) , and the nerve injury-induced proinflammatory cytokine expression in microglia and the subsequent pain hypersensitivity is abrogated by the inhibition of p38 (12) . In addition, we have recently discovered that NADPH oxidase 2 (Nox2) is induced in spinal cord microglia after nerve injury, and that Nox2-derived reactive oxygen species (ROS) production is required for nerve injury-induced microglia activation and pain hypersensitivity (13) . These findings further indicate that Nox2 is an important intracellular mediator of nerve injury-induced spinal cord microglia activation. However, it is currently not clear how Nox2 is upregulated in spinal cord microglia after nerve injury. Based on the studies implicating TLRs as microglial activation receptors which respond to nerve injury (8) (9) (10) , we hypothesized that TLRs might be involved in nerve injury-induced Nox2 expression in spinal cord microglia. To investigate this hypothesis, our study design used knock-out mice of different TLR genes that have been implicated in nerve injury-induced spinal cord microglia activation (e.g., TLR2, 3, or 4 knock-out mice). Our data show that TLR2 plays a critical role in nerve injury-induced Nox2 expression in spinal cord microglia.
EXPERIMENTAL PROCEDURES
Animals and Surgery -All surgical and experimental procedures were reviewed and approved by the Institutional Animal Care and Use Committee at Seoul National University. The animal treatments were performed in accordance with the guidelines of the International Association for the Study of Pain. All mice were housed in an animal facility with a specific pathogen-free barrier under a 12-h light-dark cycle. Mice were allowed to access food and water ad libitum. Wild-type (WT), TLR2, 3, or 4 knock-out, and MyD88 knock-out mice of C57BL/6 background aged 8-12 weeks were used. Peripheral nerve injury was induced by transecting the L5 spinal nerve (L5 SNT) under anesthesia with pentobarbital sodium (50 mg/kg, i.p.) as previously described (13) . In brief, an incision was made in the skin from the spinal processes at L4 to S2 levels. The paraspinal muscles were separated and the L6 transverse process was partially removed. The L5 spinal nerve was transected carefully upon exposure and then the surgical site was closed in two layers with surgical staples. The sham operation was performed as described above but in the absence of transecting the L5 spinal nerve. The mice operated on were monitored on a warm pad during recovery.
Real-time RT-PCR -Real-time RT-PCR was performed using SYBR Green PCR Master Mix and an ABI Prism 7300 sequence detection system (Applied Biosystems, Foster City, CA, USA) as previously described (13) . The following PCR primer sequences were used: mouse/rat GAPDH forward, 5 '-AGG TCA TCC CAG AGC TGA ACG-3'; mouse/rat GAPDH  reverse, 5'-CAC CCT GTT GCT GTA GCC  GTA T-3'; mouse Nox2 forward, 5'-GAC CCA  GAT GCA GGA AAG GAA-3'; mouse Nox2  reverse, 5'-TCA TGG TGC ACA GCA AAG  TGA T-3'; rat Nox2 forward, 5'-TGC AAG  TCA ACA CCC CAA CA-3'; rat Nox2 reverse,  5'-CGG ACT CAG AGT TGG AGA TGC T-3'. Duplicate reactions were performed, each containing 10 pmol primer, 4 µl cDNA, and 5 µl of 2× SYBR Green PCR Master Mix (Applied Biosystems) in a total volume of 10 µl. The mRNA level of the Nox2 gene was normalized to the corresponding level of GAPDH and represented as the fold induction, which was calculated using the 2 -ΔΔCT method as previously described (14) . All real-time RT-PCR experiments were performed at least three times, and the mean ± SEM values are presented unless otherwise noted.
Immunohistochemistry -Mice were deeply anesthetized with pentobarbital sodium (50 mg/kg, i.p.) and transcardially perfused with 4% paraformaldehyde (PFA) in 0.1 M phosphate buffer (pH 7.4). The L5 spinal cord was removed, postfixed in 4% PFA at 4°C overnight, and transferred to a 30% sucrose phosphate buffer for 48 h. Spinal cord transverse sections (14 µm-thick) were prepared on a gelatin-coated slide glass using a cryocut microtome. The sections were blocked in a solution containing 5% normal goat serum (Jackson Immuno-Research, Bar Harbor, ME, USA), 2% BSA (Sigma, St. Louis, MO, USA), and 0.1% Triton X-100 (Sigma) for 1 h at room temperature. The sections were then incubated overnight at 4°C with primary antibody for mouse-anti-Nox2 (1:100, Santa Cruz Biotechnology, Delaware Avenue, CA, USA), rabbit-anti-Iba-1 (1:1000, Wako, Osaka, Japan), mouse-anti-8-OHG (1:1,500, Abcam, Cambridge, MA, USA), rabbit-anti-GFAP (1:5,000, DAKO, Glostrup, Denmark), rabbit-anti-MAP2 (1:2,000, Millipore, Billerica, MA, USA), and rabbit-anti-NG2 (1:200, Millipore). After rinsing in 0.1 M PBS, the sections were incubated for 1 h at room temperature with a mixture of FITCconjugated or Cy3-conjugated secondary antibodies (1:200, Jackson Immuno-Research). The sections were mounted using Vectashield mounting medium (Vector Laboratories, Burlingame, CA, USA), and fluorescent images were obtained with a confocal microscope (LSM700, Carl Zeiss, Germany). Fluorescent signal intensity was quantified using ImageJ software (National Institutes of Health, Bethesda, MD, USA).
Intrathecal injection -For the administration of lipoteichoic acid (LTA, Sigma) and SB202190 (Sigma), mice were injected under pentobarbital sodium anesthesia (25 mg/kg, i.p.) by direct lumbar puncture between the L5 and L6 vertebrae of the spine, using a 10-µl Hamilton syringe (Hamilton Company, Reno, NV, USA) with a 30G 1/2" needle as previously described (15) . 5 µl of 50 µg/ml LTA in PBS or PBS alone was intrathecally injected in WT and TLR2 knock-out mice. LTA was preincubated with polymyxin B (PMB, 10 µg/ml) for 30 min at 37°C before use to prevent LPS contamination. SB202190 was dissolved in DMSO at 25 mg/ml and diluted in 0.9% saline solution. 10 µl of 1 mg/ml SB202190 in saline solution or vehicle alone was injected in WT mice before L5 SNT. The success of the intrathecal injection was assessed by monitoring the tail-flicking response of the animal when the needle penetrated the subarachnoid space.
Primary cell culture -Primary mixed glial and microglial cell cultures were prepared according to previously established procedures (8, 16) . In brief, primary spinal cord glial cells were prepared from 7-day-old Sprague-Dawley rats. After the rats were anesthetized, their spines were extirpated, a syringe with PBS (pH 7.4) was inserted, and the spinal cord was pushed out by hydraulic pressure. Upon stripping off the meninges from the spinal cord, the spinal cord was dissociated into single cells by repetitive pipetting and incubation in glial cell culture medium (DMEM supplemented with 10 mM HEPES, 10% FBS, 2 mM L-glutamine, and 1× antibiotic-antimycotic) in a 75-cm 2 flask at 37°C in a 5% CO 2 incubator. The medium was changed every five days thereafter. After two weeks, the glial cells were trypsinized and seeded in six-well plates for subsequent use. Primary brain glial cell cultures were prepared from postnatal day 1-3 C57BL/6 mice. The meninges were removed from the cerebral hemispheres, dissociated into single cells by trituration, and incubated in glial cell culture medium in a 75-cm 2 flask at 37°C in a 5% CO 2 incubator. Primary microglia were harvested from mixed glial cultures on day 14. After shaking at 200 r.p.m. for 3 h on an orbital shaker, the media from the cultures was collected and centrifuged at 800 r.p.m. for 5 min. Microglia were plated in glial culture media. After 15 min, the dishes were washed with medium to remove any unattached astrocytes. The purity of the microglia was routinely monitored and determined to be >98% after immunostaining with Iba-1 antibody (1:1000, Wako).
Western blot analysis -Primary rat spinal cord glial cells or mouse brain glial cells stimulated with LTA for various periods of time were harvested with lysis buffer (50 mM Tris-Cl, pH 7.5, 150 mM NaCl, 1% Triton X-100, 10% glycerol, protease inhibitor mixture (GBiosciences, St Louis, MO, USA) and phosphatase inhibitor cocktail set IV (Millipore)). 20 or 30 µg of the cell lysate from each sample was resolved using electrophoresis on a 10% SDS-PAGE. The proteins separated based on size were transferred to a nitrocellulose membrane, which was then blocked with 5% non-fat dry milk in Tris-buffered saline containing Tween 20 (TBST, 20 mM Tris, pH 7.4, 0.1% Tween 20, and 150 mM NaCl). The membrane were probed overnight with primary antibody for mouse-anti-Nox2 (1:1000, Millipore) or rabbit-anti-phospho-eIF4E [Ser209] (1:1000, Cell signaling Technology, Danvers, MA, USA) at 4°C, followed by incubation with horseradish peroxidase-conjugated secondary antibody at room temperature for 1 h prior to ECL (GE Healthcare, Buckinghamshire, UK) treatment. The signal was detected by MicroChemi (DNR Bio-imaging Systems, Israel). For the normalization of the antibody signal, the membranes were stripped and reprobed with antibody for β-actin (1:2000, Sigma).
Intracellular ROS measurement -
Intracellular ROS production in spinal cord glial cells was measured using cell permeable fluorescent dye, CM-H 2 DCFDA (Life technologies, Grand Island, NY, USA), after TLR2 stimulation. At 12 h after LTA (2 µg/ml) treatment, CM-H 2 DCFDA (10 µM) was loaded in glial cells and incubated for 45 min at 37°C. Upon rinsing the spinal cord glial cells with PBS, the fluorescent intensity was measured at the excitation wavelength of 485 nm and the emission wavelength of 520 nm. The three experiments were independently performed and each experiment was performed in triplicate.
Statistical analysis -The statistical significance of differences was assessed using SigmaPlot software (version 11.0, Systat Software, Inc., San Jose, CA, USA). Statistical analysis was performed using the Student's ttest. All data are presented as the mean ± SEM, and differences were considered statistically significant when the p-value was less than 0.05.
RESULTS

Nerve injury-induced Nox2 expression
is abrogated in TLR2 knock-out mice -TLR2, 3, or 4 knock-out mice were utilized to evaluate if TLRs are involved in Nox2 expression in spinal cord microglia after spinal nerve injury. All these genes have been implicated in spinal cord microglia activation after spinal nerve injury (8) (9) (10) . L5 spinal nerve axotomy, a well-known mouse neuropathic pain model, induced Nox2 mRNA expression in the L5 spinal cord region of WT mice by 2-fold at 12 and 24 h (Fig. 1A) . Similar levels of Nox2 mRNA induction were detected in the spinal cord of TLR3 or 4 knockout mice. However, nerve injury-mediated Nox2 mRNA induction was completely abrogated in the spinal cord of TLR2 knock-out mice. Likewise, Nox2 protein expression, measured by immunohistochemistry, was upregulated in the dorsal horn of the ipsilateral spinal cord of WT mice at 1 day post injury (dpi) (Fig. 1B) . The Nox2-immunoreactivity (IR) mainly colocalized to Iba-1-IR microglia (Fig. 1B, merged  panels) . In contrast, L5 spinal nerve injury failed to induce Nox2 protein expression in the TLR2 knock-out mice. In the TLR3 and 4 knock-out mice, the levels of Nox2-upregulation detected in the ipsilateral dorsal horn were similar to that detected in WT mice (Fig. 1B) . On the other hand, Nox2-IR was not detected in the spinal cord of Nox2 knock-out mice 3 days after L5 SNT, confirming the specificity of the Nox2 antibody (Fig. 1C) . The upregulation of Nox2 accompanied ROS generation in the spinal cord of nerve-injured WT mice, but not in TLR2 knock-out mice (Fig. 1D) . These data suggest that TLR2, but not TLR3 or 4, is required for nerve injury-induced Nox2 upregulation in microglia and the subsequent ROS production in the dorsal horn.
TLR2 stimulation induces Nox2 upregulation in the spinal cord in vivo -
To assess whether or not TLR2 activation can induce Nox2 expression in spinal cord microglia in vivo, LTA, a TLR2 agonist, was introduced intrathecally in WT and TLR2 knock-out mice. Twelve hours after LTA administration, Nox2 mRNA was upregulated by 7-fold in the WT spinal cord, but was not induced in the TLR2 knock-out spinal cord ( Fig. 2A) . Likewise, Nox2 protein was upregulated by the intrathecal injection of LTA in the spinal cord of WT mice, but not in that of TLR2 knock-out mice (Fig.  2B) . Nox2 was mainly expressed in the Iba-1-positive microglia (Fig. 2B, merged panels) . These data indicate that TLR2 activation in spinal cord cells can induce Nox2 expression in microglia.
TLR2 is expressed only in microglia in
the spinal cord -In order to identify the cell types that express TLR2 in the spinal cord, immunohistochemistry was performed. When nerve injury was not induced, TLR2 expression was detected at very low levels in the spinal cord, whereas it was upregluated following L5 SNT (Fig. 3A) . Furthermore, the enhanced TLR2-IR mainly co-localized with Iba-1-IR microglia, but not with glial fibrillary acidic protein (GFAP)-positive astrocytes, microtubule-associated protein 2 (MAP2)-positive neurons, or NG2-positive oligodendrocyte progenitor cells (Fig. 3B) , indicating that TLR2 is expressed exclusively in microglia in the spinal cord. No obvious TLR2-IR signal was detected upon immunostaining spinal cord sections from TLR2 knock-out mice, confirming the specificity of the TLR2 antibody (Fig. 3A) . Taken together, these data suggest that LTA introduction in the spinal cord induces microglial Nox2 expression by directly stimulating TLR2 on the spinal cord microglia. Fig. 4A and B) . As measured by western blot assay, LTA stimulation also increased Nox2 protein levels in spinal glial cells (Fig. 4C ). In addition, LTA stimulation increased intracellular ROS production in spinal cord glial cells by more than 2-fold (Fig. 4D ). These data demonstrate that TLR2 stimulation induces Nox2 expression and ROS production in microglia.
TLR2 stimulation induces
Nox2 expression in primary spinal cord glia -Primary mixed glial cells and microglia were cultured from rat spinal cord and mice cerebra, respectively, and then stimulated with LTA to further investigate TLR2-mediated Nox2 gene expression in spinal cord microglia. After LTA stimulation for 3 h, Nox2 mRNA was induced in primary spinal cord mixed glial cells and primary microglia by 2-fold and 4-fold, respectively (
NF-κB and p38 activation is involved in TLR2-activated Nox2 expression in glia -
We then characterized the intracellular signaling pathways that mediate TLR2-induced Nox2 gene expression. It is well-known that TLR2 induces activation of NF-κB and MAP kinases in microglia in vitro (17, 18) . Accordingly, we used pharmacological inhibitors to test the involvement of these signaling molecules in TLR2-activated Nox2 mRNA expression. Helenalin, a NF-κB inhibitor, inhibited LTAinduced Nox2 mRNA induction by more than 80% (Fig. 5A) , indicating that NF-κB activation is required for TLR2-induced Nox2 transcription. However, the induction level was not significantly affected by the pretreatment of U0126 (ERK inhibitor), SB202190 (p38 inhibitor), or SP600125 (JNK inhibitor). Likewise, LTA stimulation increased Nox2 protein expression by more than 5-fold in primary glial cells (Fig. 5B) . The protein induction level was partially reduced by the treatment of NF-κB inhibitor by up to 35%, but almost completely blocked by p38 inhibitor (Fig. 5C ). Neither ERK nor JNK inhibitors significantly affected Nox2 protein expression. These data suggest that p38 activation induces Nox2 expression at the translational level. It is known that p38 regulates translation by activating eukaryotic translation initiation factor 4E (eIF4E) (19) . In brain glia, TLR2 stimulation induced activation of eIF4E as early as 30 min, which was measured by phosphorylated eIF4E (Fig. 5D) . The TLR2-induced eIF4E phosphorylation was almost completely blocked by p38 inhibitor (Fig. 5E and F) , indicating that p38 MAPK may increase Nox2 expression at the translational level via eIF4E activation.
To determine if p38 activation is also required for nerve injury-induced Nox2 expression in spinal cord microglia in vivo, we introduced SB202190 into the spinal cord intrathecally. Upon SB202190 injection, nerve injury-induced Nox2 upregulation in the spinal cord microglia was nearly completely abrogated (Fig. 6A) . These data show that p38 activation is necessary for nerve injury-induced Nox2 expression in spinal cord microglia in vivo. TLR2 transmits intracellular signals via MyD88 (20) . In this regard, we tested if MyD88 is required for nerve injury-induced Nox2 expression using MyD88 knock-out mice. As expected, the spinal cord microglial Nox2 expression was almost completely blocked in the MyD88 knock-out mice (Fig. 6B) . Taken together, these data indicate that peripheral nerve injury induces spinal cord microglial Nox2 expression via TLR2-MyD88 signaling pathways.
DISCUSSION
The results from this study demonstrate that TLR2 is required for Nox2 expression in spinal cord microglia after L5 spinal nerve injury, playing a critical role in microglia activation and the subsequent induction of neuropathic pain (13) . Our data suggest that Nox2 gene expression in spinal cord microglia is due to TLR2-MyD88 activation upon nerve injury. Interestingly, although TLR2, 3, and 4 are all implicated in microglia activation after peripheral nerve injury (8-10), the L5 SNTinduced Nox2 upregulation was only absent in TLR2 knock-out mice. Meanwhile, Nox2 expression in TLR3 or 4 knock-out mice was comparable to the levels found in WT mice. Even so, nerve injury-induced spinal cord microglia activation and pain induction was still compromised in TLR3 and 4 knock-out mice, (9, 10) . These data suggest that the pain potentiating mechanisms of TLR2, 3, and 4 are not redundant; TLR2 may contribute to pain hypersensitivity via Nox2 induction in spinal cord microglia, whereas TLR3 and 4 may affect central sensitization via other pathways. Unlike TLR2, TLR3 and 4 trigger intracellular signals via TRIF in addition to MyD88 (21) , which may explain the differences between them. In this regard, it will be worthwhile to investigate if the SNT-induced neuropathic pain is completely blocked in TLR2 and 3 or TLR2 and 4 double knock-out mice.
Although our data from the TLR2 knock-out mice point to the important role of microglial TLR2 in Nox2 expression, at this point, we cannot exclude the possibility that TLR2 on peripheral immune cells may indirectly affect Nox2 expression in spinal cord microglia. However, our study utilized intrathecal LTA administration, which supposedly affects cells in the spinal cord rather than peripheral immune cells, suggesting that TLR2 activation in spinal cord cells leads to Nox2 induction in microglia. In conjunction with these data, our immunohistochemistry data illustrate that TLR2 is solely expressed on microglia in the spinal cord but not in other spinal cord glia or neurons. This is consistent with a previous report that showed that TLR2 expression was only present in microglia of spinal cord tissues from amyotrophic lateral sclerosis (ALS) patients (22) . Given the cellular localization of TLR2 in the spinal cord, it is reasonable to speculate that TLR2 activation on microglia by intrathecal LTA injection directly activates Nox2 expression in microglia. From these data, it can be inferred that TLR2 activation on spinal cord microglia leads to Nox2 expression after L5 SNT. However, it is not clear how microglial TLR2 is activated during peripheral nerve injury. One possibility is that a certain endogenous TLR2 ligand is released from damaged primary afferent neurons after L5 SNT, and thereby activates TLR2 on spinal cord microglia. To date, various endogenous TLR2 agonists have been documented, including heat shock proteins, hyaluronic acid, and high mobility group box-1 protein (23) . However, there is no evidence implicating any of these TLR2 endogenous agonists in the development of nerve injuryinduced neuropathic pain. Instead, other putative microglia activating molecules such as fractalkine, ATP, and glutamate have been reported to be released from damaged sensory neurons after nerve injury (6, 24) . However, in our study, fractalkine, ATP, and glutamate were not able to induce Nox2 mRNA expression in primary spinal cord microglia (data not shown). Thus, it is likely that, in addition to the above activators, currently unidentified endogenous TLR2 agonist molecules are involved in spinal cord microglia activation during peripheral nerve injury. Accordingly, future research to determine if any TLR2 endogenous agonist molecules are released in the spinal cord dorsal horn upon peripheral nerve injury is of importance.
To our knowledge, our in vitro study using primary cultured microglia showed, for the first time, that TLR2 activation on microglia is able to induce Nox2 gene expression. Additionally, our results revealed that NF-κB and p38 MAP kinase differentially regulate TLR2-induced Nox2 gene expression; NF-κB at the transcriptional level vs. p38 at the translational level. Transcriptional regulatory mechanisms of Nox2 gene expression have been previously documented. For instance, interferon-γ (IFN-γ) induces Nox2 expression in monocytes by phosphorylating PU.1 in the PKC-dependent pathway (25) . In addition, LPS/IFN-γ stimulation can induce Nox2 expression in monocytes via NF-κB activation (26) . However, to our knowledge, translational regulation of the Nox2 gene has not been reported. Our in vitro data further contribute to the literature on the regulatory mechanisms of Nox2 gene expression by elucidating novel regulatory mechanisms of Nox2 that is dependent on the TLR2-p38 signaling pathway. Of note, in our in vitro study, NF-κB inhibitor only partially inhibited TLR2-induced Nox2 protein expression while it almost completely blocked mRNA induction. Since there is constitutive Nox2 mRNA expression, it can be assumed that p38 activation alone, in the presence of NF-κB inhibitor, is able to increase Nox2 protein by activating translation from the constitutively expressed Nox2 mRNA. It is well known that p38 MAP kinase is activated in spinal cord microglia after nerve injury (27) . p38 activation is a key signaling event that leads to pain-mediating gene expression in spinal cord microglia such as the expression of proinflammatory cytokines, Cox2, and iNOS after peripheral nerve injury and the subsequent neuropathic pain induction (28) . We have also reported that Nox2-induced ROS production is required for maximal proinflammatory cytokine expression in microglia (13) . Based on these reports, a hypothesis that merits further investigation is that the previously established functions of p38 activation on proinflammatory cytokine expression and pain hypersensitivity are at least partly due to its effects on Nox2 expression.
In conclusion, we found that TLR2 is required for Nox2 expression in spinal cord microglia after L5 SNT. Ultimately, this finding suggests that the TLR2-MyD88-p38-Nox2 signaling pathway plays an important role in spinal cord microglial activation during the development of peripheral nerve injury-induced neuropathic pain. primary microglia were stimulated with LTA (2 µg/ml) for 3 h. Total RNA was prepared from each sample and used for real-time RT-PCR to measure Nox2 mRNA expression. Three independent experiments were performed using primary cells cultured from different donors. The Nox2 transcript level is presented as the fold induction and data are expressed as mean ± SEM (Student's t-test, **, p < 0.01; ***, p < 0.001). C. Nox2 protein expression was determined by western blot assay in primary spinal cord glial cells at 6 and 12 h after LTA (2 µg/ml) treatment. β-actin was used as a loading control. D. Intracellular ROS production in spinal cord glial cells was measured using cell permeable fluorescent dye, CM-H 2 DCFDA (10 µM), after TLR2 stimulation. At 12 h after LTA (2 µg/ml) treatment, intracellular ROS generation was increased in spinal cord glial cells. Data are represented as mean ± SEM (Student's t-test, ***, p < 0.001).
FIGURE 5. NF-κB and p38 MAP kinase activation is required for Nox2 expression after TLR2 stimulation. A. Primary mouse brain glial cells were stimulated with LTA (2 µg/ml) for 3 h in the presence or absence of the following NF-κB or MAPKs inhibitors: Hel (Helenalin, NF-κB inhibitor, 5 µM), U (U0126, ERK inhibitor, 5 µM), SB (SB202190, p38 inhibitor, 5 µM), and SP (SP600125, JNK inhibitor, 5 µM). The inhibitors were pretreated for 1 h prior to the LTA stimulation. Total RNA was isolated from each sample and used to analyze Nox2 mRNA transcript level by real-time RT-PCR. Data are expressed as mean ± SEM (Student's t-test, ***, p < 0.001). B. Brain glial cells were stimulated with LTA (2 µg/ml) for 6 h with or without NF-κB or MAPKs inhibitors. Cell lysates were prepared from each sample and used for western blot analysis to measure Nox2 expression. Three independent experiments were performed and a representative western blot image is shown. C. The band intensity of the Nox2 protein was measured and presented as the fold increase compared with the control, which was normalized to the intensity of β-actin (Student's t-test, *, p < 0.05; ***, p < 0.001). D. Brain glial cells were stimulated with LTA (2 µg/ml) for various time points. Cell lysates were used to measure phosphorylated-eIF4E (p-eIF4E) by western blot analysis. E. Glial cells were stimulated with LTA (2 µg/ml) for 1 h in the presence or absence of SB202190. p38 inhibitor was pretreated for 1 h before TLR2 stimulation. Three experiments were independently performed and a representative western blot image is shown. F. The band intensity of the p-eIF4E was measured and normalized to the corresponding intensity of β-actin. Data are represented as fold increase compared to the control (Student's t-test, ***, p < 0.001). 
